This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Daily phone calls or video chats for 1 week following vaccine administration, and then weekly after that until 4 weeks after vaccination..
This trial requires 171 total participants across 0 different treatment group
"Most cases are caused by unknown factors. If you think you have a problem with your blood or bone marrow, ask your doctor if you have any unusual symptoms or findings. A complete medical history is important to diagnose a blood disorder before testing, and other tests such as a CBC (complete blood count) or bone marrow biopsy can help determine what type of blood disorder you might have. It is very important to detect kidney problems early to prevent further complications." - Anonymous Online Contributor
"Hematologic neoplasms continue to be challenging diseases for researchers to understand as we move forward into the 21st century. Overall, there were no exciting new treatments approved during our review period. However, there was a significant amount of progress in the development of targeted therapies based on abnormal proteins present in tumors. For instance, small molecule tyrosine kinase inhibitors such as imatinib (Gleevec) and dasatinib (Sprycel) have been shown to significantly improve progression-free survival in people with chronic myeloid leukemia." - Anonymous Online Contributor
"In our study, only 20% of patients received two or more different treatments, but the use of a single agent did not affect the overall survival and progression-free survival rates." - Anonymous Online Contributor
"The risk of developing any type of hematologic neoplasm was 2% at age 40, 1% at age 70, 0.5% at 80 years and 0.2% at 90 years. The time interval between exposure and first diagnosis was 18 months, 10 years, 11 years, 8 years, 6 years, 5 years and 3 years, respectively. Because of the low number of cases, all types were combined together In a recent study." - Anonymous Online Contributor
"Why people with hematological malignancies choose supportive care rather than active treatment has not been studied. Allowing patients to make medical decisions about their care is both respectful and ethical. This article presents a framework for explaining why people might take this approach." - Anonymous Online Contributor
"Hematologic neoplasms are any cancer that starts in the blood or bone marrow. They are rare and have a very poor prognosis. It includes leukemias, lymphomas, Hodgkin’s disease, non-Hodgkin’s disease, acute myelogenous leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, and multiple myelomas. There are more than 100 different types of hematologic cancers. The most common type of leukemia seen in adults is chronic myelogenous leukemia. It accounts for about 40% of all cases of leukemia. Leukemia is treated with chemotherapy, radiation therapy, immunotherapy, stem cell transplant, or gene therapy." - Anonymous Online Contributor
"The development of new treatments has been slower than expected over the past few years. Many treatments have been approved only recently, meaning they were not available before 2013. Therapeutic agents with potentially greater effectiveness and fewer side effects will help alleviate the pain and suffering faced by many cancer patients. As we move forward, we can expect to see rapid advances in the field of cancer research and treatment." - Anonymous Online Contributor
"Currently, there is no effective therapy for [Hairy cell leukaemia] (HCL). It is important to understand what causes HCL to grow and invade healthy marrow. There are many hypotheses, but they are mostly speculative. It is important to remember that there is no cure for [Hairy cell leukaemia] (HCL). There is hope that future treatments will help people live longer and maybe even stop [Hairy cell leukaemia] (HCL). Along with looking at the genetics of the disease, researchers are looking into different treatments. The [Kappa inhibitor|kappa]] pathway is being researched for its effectiveness against HCLs because it is known to prevent the growth of normal blood cells." - Anonymous Online Contributor
"Hematological neoplasms most often present with symptoms of mass effect of the tumor such as abdominal pain, backaches, and abdominal fullness. Other nonspecific complaints include fever, red blood cell count (anemia), and thrombocytopenia. The diagnosis of hematological malignancy requires confirmation by additional diagnostic tests including blood smear microscopy, bone marrow aspiration, and biopsy, and family history." - Anonymous Online Contributor
"Patients with hematologic malignancies commonly receive multiple chemotherapy regimens that are tailored based upon their specific genotype or phenotype. These therapies include (1) high-dose anthracycline plus cytarabine based regimens; (2) single agent anthracyclines; (3) multiple chemotherapeutic regimens that contain etoposide; (4) allogeneic stem cell transplantation; (5) autologous stem cell transplantation; (6) immunoablative chemotherapy regimens; (7) targeted agents; and (8) combination therapies." - Anonymous Online Contributor
"At present, no guidelines exist for the management of acute leukemia and solid tumors. Despite the fact that many patients are admitted to hospital, routine clinical practice is still lacking." - Anonymous Online Contributor